|Table of Contents|

The research progress of anti-PD-(L)1 and anti-CTLA-4 immunotherapy markers

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 02
Page:
346-350
Research Field:
Publishing date:

Info

Title:
The research progress of anti-PD-(L)1 and anti-CTLA-4 immunotherapy markers
Author(s):
Wang Chengchen; Chen Xiaopin
The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016，China.
Keywords:
immunotherapy; PD-L1 expression; tumor infiltrating lymphocytes; mutational load; peripheral blood markers
PACS:
R730.51
DOI:
10.3969/j.issn.1672-4992.2020.02.039
Abstract:
Immune checkpoint inhibitors have changed the treatment of many tumors，including lung cancer and melanoma，and have shown a sustained response in some refractory tumors.However，some of the patients who received treatment showed no response and severe immune-related side effects.In order to optimize the use of immunotherapy，multiple predictive markers of clinical response may be required.We review here the data available for several potentially effective biomarkers.Detecting the expression of PD-L1 in tumor cells and immune cells by immunohistochemistry is a good predictor of clinical efficacy.However some patients with negative PD-L1 expression can still benefit from immunotherapy,for the existence of different antibodies，different thresholds and different targets.Moreover，the expression of PD-L1 is dynamic and heterogeneous in tumor.It is not consistent between primary focus and metastasis，or between puncture specimen and gross specimen.The high ratio of mutation load to new antigen is also associated with improved response.Peripheral blood markers could also provide information that increased absolute lymphocyte counts were significantly associated with disease control and survival.In this review，we aim to discuss the current status of research on anti-PD-(L)1 and anti CTLA-4 immunotherapy，to provide guidance for clinical practice，so that more patients can benefit from these treatments.

References:

［1］ Balar AV，Castellano D，O'Donnell PH，et al.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer（KEYNOTE-052)：A multicentre，single-arm，phase 2 study［J］.Lancet Oncol，2017，18(11)：1483-1492.
［2］ Borghaei H，Paz-Ares L，Horn L，et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.N Engl J Med，2015，373(17)：1627-1639.
［3］ Reck M，Rodríguez-Abreu D，Robinson AG，et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］.N Engl J Med，2016，375(19)：1823-1833.
［4］ Larkin J，Chiarion-Sileni V，Gonzalez R，et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma［J］.N Engl J Med，2015，373(1)：23-34.
［5］ Smithy JW，Moore LM，Pelekanou V，et al.Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma［J］.J Immunother Cancer，2017（5）：25.
［6］ Kowanetz M，Zou W，Gettinger SN，et al.Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab（anti-PD-L1)［J］.PNAS，115（43）：E10119-E10126.
［7］ Powles T，Eder JP，Fine GD，et al.MPDL3280A（anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer［J］.Nature，2014，515(7528)：558-562.
［8］ Losa NL，Cruise M，Tam A，et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints［J］.Cancer Discov，2015，5(1)：43-51.
［9］ Carbognin L，Pilotto S，Milella M，et al.Differential activity of nivolumab，pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1（PD-L1)：Sensitivity analysis of trials in melanoma，lung and genitourinary cancers［J］.PLoS One，2015，10(6)：e0130142.
［10］ Chen J，Jiang CC，Jin L，et al.Regulation of PD-L1：A novel role of pro-survival signalling in cancer［J］.Ann Oncol，2015，27(3)：409-416.
［11］ Ansell SM，Lesokhin AM，Borrello I，et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma［J］.N Engl J Med，2015，372(4)：311-319.
［12］ Zhang Y，Chen LP.Classification of advanced human cancers based on tumor immunity in the microenvironment（TIME) for cancer immunotherapy［J］.JAMA Oncol，2016，2(11)：1403-1404.
［13］ Chen DS，Mellman I.Elements of cancer immunity and the cancer-immune set point［J］.Nature，2017，541(7637)：321-330.
［14］ Teng MW，Ngiow SF，Ribas A，et al.Classifying cancers based on T-cell infiltration and PD-L1［J］.Cancer Res，2015，75(11)：2139-2145.
［15］ Solomon B，Young RJ，Bressel M，et al.Prognostic significance of PD-L1+ and CD8+ immune cells in HPV+ oropharyngeal squamous cell carcinoma［J/OL］.Cancer Immunol Res.（2018-01-27) ［2018-10-25］.http://cancerimmunolres.aacrjournals.org/content/early/2018/01/27/2326-6066.CIR-17-0299.full-text.pdf.
［16］ Tremblay-LeMay R，Rastgoo N，Chang H.Modulating PD-L1 expression in multiple myeloma：An alternative strategy to target the PD-1/PD-L1 pathway［J］.J Hematol Oncol，2018（11）：46.
［17］ Teng FF，Meng XJ，Kong L，et al.Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy：A systematic review［J］.Cancer Lett，2018（414）：166-173.
［18］ Abril-Rodriguez G，Ribas A.SnapShot：Immune checkpoint inhibitors［J］.Cancer Cell，2017，31(6)：848.
［19］ Gao Y，Yang JJ，Cai YX，et al.IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling［J］.Int J Cancer，2018，143(4)：931-943.
［20］ Snyder A，Makarov V，Merghoub T，et al.Genetic basis for clinical response to CTLA-4 blockade in melanoma［J］.New Engl J Med，2014，371(23)：2189-2199.
［21］ Rizvi NA，Hellmann MD，Snyder A，et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］.Science，2015，348(6230)：124-128.
［22］ McGranahan N，Furness AJ，Rosenthal R，et al.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade［J］.Science，2016，351(6280)：1463-1469.
［23］ Le DT，Uram JN，Wang H，et al.PD-1 blockade in tumors with mismatch-repair deficiency［J］.New Engl J Med，2015，372(26)：2509-2520.
［24］ Overman MJ，McDermott R，Leach JL，et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer（CheckMate 142)：An open-label，multicentre，phase 2 study［J］.Lancet Oncol，2017，18(9)：1182-1191.
［25］ Le DT，Durham JN，Smith KN，et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［J］.Science，2017，357(6349)：409-413.
［26］ Mehnert JM，Panda A，Zhong H，et al.Exceptional response to PD-1 antibody treatment in a POLE-mutant endometrial cancer［J］.Mol Cancer Ther，2015，14(12)：PR05.
［27］ Diem S，Kasenda B，Spain L，et al.Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma［J］.Br J Cancer，2016，114(3)：256-261.
［28］ Dick J，Lang N，Slynko A，et al.Use of LDH and autoimmune side effects to predict response to ipilimumab treatment［J］.Immunotherapy，2016，8(9):1033-1044.
［29］ Long GV，Grob JJ，Nathan P，et al.Factors predictive of response，disease progression，and overall survival after dabrafenib and trametinib combination treatment：A pooled analysis of individual patient data from randomised trials［J］.Lancet Oncol，2016，17(12)：1743-1754.
［30］ Ferrucci PF，Ascierto PA，Pigozzo J，et al.Baseline neutrophils and derived neutrophil-to-lymphocyte ratio：Prognostic relevance in metastatic melanoma patients receiving ipilimumab［J］.Ann Oncol，2016，27(4)：732-738.
［31］ Fujisawa Y，Yoshino K，Otsuka A，et al.Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population［J］.Br J Dermatol，2018，179(1)：213-215.
［32］ Diem S，Schmid S，Krapf M，et al.Neutrophil-to-lymphocyte ratio（NLR) and platelet-to-lymphocyte ratio（PLR) as prognostic markers in patients with non-small cell lung cancer（NSCLC) treated with nivolumab［J］.Lung Cancer，2017(111)：176-181.
［33］ Jeyakumar G，Kim S，Bumma N，et al.Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy［J］.J Immunother Cancer，2017，5(1)：82.
［34］ Huber V，Vallacchi V，Fleming V，et al.Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma［J/OL］.J Clin Invest.（2018-09-27) ［2018-10-25］.http://www.jci.org/articles/view/98060/pdf.
［35］ Rosales C.Neutrophil：A cell with many roles in inflammation or several cell types［J］?Front Physiol，2018(9)：113.
［36］ Gebhardt C，Sevko A，Jiang H，et al.Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab［J］.Clin Cancer Res，2015，21(24):5453-5459.

Memo

Memo:
-
Last Update: 2019-11-29